• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Denali acquires F-star Gamma and its antibody tech to help drugs cross the blood-brain barrier

May 30, 2018 By Sarah Faulkner

F-starPrivately-held biopharma F-star said today that its partner, Denali Therapeutics (NSDQ:DNLI), chose to exercise its option to buy F-Star Gamma in a deal valued at approximately $471 million.

The two companies first inked a collaboration in August 2016 to develop antibody technologies that help drugs cross the blood-brain barrier.

“When you give an antibody via IV injection, it does not readily go into the central nervous system,” F-star CEO John Haurum told Drug Delivery Business News.

Denali wants to take advantage of transporter molecules that cross the blood-brain barrier to address this long-standing therapeutic challenges – F-star sees its antibody tech as a way to target and hone in on these transporter molecules.

For example, one target that F-star Gamma and Denali have been working on is the transferrin receptor, a protein that helps regulate iron uptake into cells. F-star Gamma is working to generate antibodies that are engineered to bind specifically to particular receptors – like the transferrin receptor –  which Denali can then use to pull its biologic therapies into the brain.

According to the terms of the deal, Denali will gain exclusive rights to the antibodies developed as part of the collaboration. Denali plans to pay $24 million upfront, plus $447 million more upon achievement of future milestones. The acquisition includes three potential targets, including the transferrin target.

“Our decision to exercise the option to buy F-star Gamma reflects the progress in our collaboration with F-star and the generation of data showing that our proprietary transport vehicle (TV) platform technology will enable us to deliver biologics across the BBB and into the brain. Furthermore, the expanded collaboration allows us to deepen and broaden our research efforts supporting our BBB platform technology,” Denali CEO Ryan Watts said in prepared remarks. 

“We are thrilled,” Haurum added. “It’s a great day for the company and for the shareholders and also, I hope, for the patients.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Mergers & Acquisitions, Neurological, Pharmaceuticals Tagged With: denalitherapeutics, fstar

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS